Source comparison
CJC-1295 No DAC & Ipamorelin vs Tesamorelin: Side-by-Side Comparison
The table below distills mechanism, dosing, half-life, clinical endpoints, and regulatory status for direct comparison. Mechanism of Action Dual-pathway: GHRH receptor (CJC) + ghrelin receptor/GHS-R1a (ipamorelin) Single-pathway: GHRH receptor agonist only Com
This comparison does not assign a generated winner or score.
- The table below distills mechanism, dosing, half-life, clinical endpoints, and regulatory status for direct comparison.
- Mechanism of Action
- Dual-pathway: GHRH receptor (CJC) + ghrelin receptor/GHS-R1a (ipamorelin)
- Single-pathway: GHRH receptor agonist only
- Combination creates synergistic pulsatile release; tesamorelin relies on sustained single-pathway stimulation
- Half-Life
- CJC: ~30 min; Ipamorelin: ~2 hours
- 26–38 minutes
- Both require daily dosing; short half-lives prevent receptor desensitization
- Typical Research Dose
- 100–300 mcg each compound SC daily or EOD
- 2 mg SC daily (FDA-approved dosing)
- Tesamorelin dosing is standardized; combination protocols vary by study design
- Primary Endpoint Evidence
- Peak GH elevation 2.8–3× vs monotherapy; IGF-1 increase 30–60%
- VAT reduction 15.2% at 26 weeks (COSMIX trial); IGF-1 increase 44%
- Tesamorelin has FDA validation for visceral fat; combination data from smaller investigational studies
- FDA Status
- Not FDA-approved; available as research peptides
- FDA-approved (2010) for HIV-associated lipodystrophy
- Regulatory clarity favors tesamorelin for clinical applications; combination remains research-only
- Cost Per Month
- $150–$300 (combined; varies by supplier)
- $1,800–$2,500 (brand Egrifta pricing without insurance)
- Research-grade combination is significantly cheaper but lacks pharmaceutical manufacturing oversight